The Role of ALBI Score in Patients Treated with Stereotactic Body Radiotherapy for Locally Advanced Primary Liver Tumors: a Pooled Analysis of Two Prospective Studies

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Oct 18

PMID 39421444

Authors

Eleni Gkika

Gianluca Radicioni

Alexandra Eichhorst

Simon Kirste

Tanja Sprave

Nils Henrik Nicolay

Stefan Fichtner-Feigl

Robert Thimme

Rolf Wiehle

Thomas B Brunner

Anca-Ligia Grosu

Affiliations

Soon will be listed here.

Abstract

Introduction: To evaluate the outcomes after stereotactic body radiotherapy (SBRT) for locally advanced primary liver cancer.

Materials And Methods: Patients with locally advanced liver cancer unsuitable for other loco-regional treatments were treated with SBRT with 50-60 Gy in 3-12 fractions in two consecutive prospective trials.

Results: A total of 83 patients were included, of whom 14 were excluded, leaving 69 evaluable patients with 74 treated lesions. A total of 50 patients had hepatocellular carcinoma (HCC), and 11 patients had cholangiocarcinoma (CCC). Approximately 76% had a Child-Pugh (CP) score of A, while 54% had an albumin-bilirubin (ALBI) score of 1. With a median follow-up of 29 months, the median overall survival (OS) was 11 months, and the progression-free survival (PFS) was 18 months. The ALBI score was an important predictor of overall survival (HR 2.094, p = 0.001), which remained significant also in the multivariate analysis. Patients with an ALBI grade of ≥1 had an OS of 4 months versus 23 months in patients with an ALBI grade of 1 (p ≤ 0.001). The local control at 1 and 2 years was 91%. Thirteen patients developed grade ≥ 3 toxicities, of whom nine patients experienced liver toxicities. Patients with a higher ALBI score had a high risk for developing hepatic failure (OR 6.136, p = 0.006).

Discussion: SBRT is a very effective treatment with low toxicity and should be considered as a local treatment option in patients with HCC and CCC. Patients with a higher ALBI grade are at risk for developing toxicities after SBRT and have a significantly lower survival rate.

References

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

Culleton S, Jiang H, Haddad C, Kim J, Brierley J, Brade A . Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014; 111(3):412-7. DOI: 10.1016/j.radonc.2014.05.002. View

Fowler J, Tome W, Fenwick J, Mehta M . A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys. 2004; 60(4):1241-56. DOI: 10.1016/j.ijrobp.2004.07.691. View

Timmerman R . An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008; 18(4):215-22. DOI: 10.1016/j.semradonc.2008.04.001. View

Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R . Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlenther Onkol. 2017; 193(6):433-443. DOI: 10.1007/s00066-017-1099-8. View

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

Bae S, Chun S, Chung J, Kim E, Kang J, Jang W . Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines. Int J Radiat Oncol Biol Phys. 2023; 118(2):337-351. DOI: 10.1016/j.ijrobp.2023.08.015. View

Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8):646-9. DOI: 10.1002/bjs.1800600817. View

Murray L, Sykes J, Brierley J, Kim J, Wong R, Ringash J . Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys. 2018; 101(4):900-909. DOI: 10.1016/j.ijrobp.2018.04.011. View

10.

Mendez Romero A, van der Holt B, Willemssen F, de Man R, Heijmen B, Habraken S . Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial). Int J Radiat Oncol Biol Phys. 2023; 117(1):45-52. DOI: 10.1016/j.ijrobp.2023.03.064. View

11.

Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M . External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2021; 12(1):28-51. DOI: 10.1016/j.prro.2021.09.004. View

12.

Gkika E, Firat E, Adebahr S, Graf E, Popp I, Radicioni G . Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer. NPJ Precis Oncol. 2023; 7(1):24. PMC: 9981559. DOI: 10.1038/s41698-023-00358-z. View

13.

Brunner T, Nestle U, Adebahr S, Gkika E, Wiehle R, Baltas D . Simultaneous integrated protection : A new concept for high-precision radiation therapy. Strahlenther Onkol. 2016; 192(12):886-894. PMC: 5122615. DOI: 10.1007/s00066-016-1057-x. View

14.

Prayongrat A, Kobashi K, Ito Y, Katoh N, Tamura M, Dekura Y . The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients. Radiother Oncol. 2019; 135:100-106. DOI: 10.1016/j.radonc.2019.03.003. View

15.

Andolino D, Johnson C, Maluccio M, Kwo P, Tector A, Zook J . Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81(4):e447-53. DOI: 10.1016/j.ijrobp.2011.04.011. View

16.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

17.

Lee J, Shin I, Yoon W, Koom W, Rim C . Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol. 2020; 145:63-70. DOI: 10.1016/j.radonc.2019.12.004. View

18.

Gkika E, Hawkins M, Grosu A, Brunner T . The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. Front Oncol. 2020; 10:604387. PMC: 7768034. DOI: 10.3389/fonc.2020.604387. View

19.

Brunner T, Bettinger D, Schultheiss M, Maruschke L, Sturm L, Bartl N . Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol. 2021; 11:653141. PMC: 8017336. DOI: 10.3389/fonc.2021.653141. View

20.

Child C, Turcotte J . Surgery and portal hypertension. Major Probl Clin Surg. 1964; 1:1-85. View